menu
    • menu
    [{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Multi-modular Engineered Treg Cell Therapy","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Quell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Quell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"QEL-001","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Quell Therapeutics","amount2":0.16,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Quell Therapeutics \/ Jeito Capital","highestDevelopmentStatusID":"5","companyTruncated":"Quell Therapeutics \/ Jeito Capital"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Treg-based Cell Therapy","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Quell Therapeutics","amount2":2.0899999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":2.0899999999999999,"dosageForm":"","sponsorNew":"Quell Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Quell Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"QEL-001","moa":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Quell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Quell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"eXmoor pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"QEL-001","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Quell Therapeutics \/ eXmoor pharma","highestDevelopmentStatusID":"12","companyTruncated":"Quell Therapeutics \/ eXmoor pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Quell Therapeutics

    Menu

    Quell Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Quell Therapeutics

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Quell Therapeutics

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QEL-001

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : eXmoor pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Quell Therapeutics Expands CAR-Treg Manufacturing with eXmoor Pharma

                            Details : Quell & eXmoor are partnering on the process transfer, scale-up, and Phase 1/2 clinical manufacturing of multiple autologous CAR-Treg cell therapies, including QEL-001, for liver transplant patients.

                            Brand Name : QEL-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 24, 2024

                            Lead Product(s) : QEL-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : eXmoor pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Quell Therapeutics

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Quell Therapeutics

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QEL-001

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quell's QEL-001 CAR-Treg Therapy Moves to Phase 1/2 Trial for Liver Transplant Patients

                            Details : QEL-001, its autologous engineered CAR-Treg cell therapy, which is being investigated in Phase 1/2 trial in patients with liver transplant patients.

                            Brand Name : QEL-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 04, 2024

                            Lead Product(s) : QEL-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Quell Therapeutics

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Quell Therapeutics

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treg-based Cell Therapy

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : AstraZeneca

                            Deal Size : $2,085.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Astra Zeneca Announces Agreement with Quell Therapeutics to Develop, Manufacture and Commercialise Engineered ...

                            Details : The collaboration aims to focus on the type 1 diabetes and inflammatory bowel disease using Quell’s proprietary toolbox of Treg cell engineering modules, including its innovative Foxp3 Phenotype Lock, to develop autologous multi-modular Treg cell thera...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $85.0 million

                            June 09, 2023

                            Lead Product(s) : Treg-based Cell Therapy

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : AstraZeneca

                            Deal Size : $2,085.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Quell Therapeutics

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Quell Therapeutics

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QEL-001

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Jeito Capital

                            Deal Size : $156.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Mo...

                            Details : Proceeds to be used to fund clinical development of QEL-001 in liver transplantation, to accelerate development of its product pipeline across transplantation, neuroinflammatory and autoimmune diseases, and enhance its multi-modular engineered Treg platf...

                            Brand Name : QEL-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 29, 2021

                            Lead Product(s) : QEL-001

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Jeito Capital

                            Deal Size : $156.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Quell Therapeutics

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Quell Therapeutics

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Multi-modular Engineered Treg Cell Therapy

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cel...

                            Details : The QEL-001 CAR is specific for HLA-A2, which localizes the activity of the CAR-Tregs to the site of the transplanted organ in HLA-A2 mismatch liver transplant patients (i.e. HLA-A2 negative recipients who received an HLA-A2 positive donor liver).

                            Brand Name : QEL-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 27, 2021

                            Lead Product(s) : Multi-modular Engineered Treg Cell Therapy

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth